CATX

Business Context and Reporting Period

Perspective Therapeutics, Inc. (CATX) is a radiopharmaceutical development company focused on targeted alpha therapy (TAT) using Lead-212 (212Pb). The company operates in a single segment following the divestiture of its Cesium-131 brachytherapy business (Isoray) to GT Medical Technologies in April 2024, which is now reported as discontinued operations. This summary covers the quarterly period ended June 30, 2025.

Key Financial Metrics

Cash Flow (Six Months Ended June 30, 2025):

• Net cash used in operating activities: $(41.54) million
• Net cash used in investing activities: $(1.30) million
• Net cash provided by financing activities: $10.11 million (primarily from ATM sales)

Material Changes vs. Prior Period

• Revenue: Grant revenue decreased to $0.29 million in Q2 2025 from $0.53 million in Q2 2024. The company has no commercial product sales.
• Operating Expenses: Total operating expenses increased significantly to $24.33 million in Q2 2025 from $14.79 million in Q2 2024.
  • R&D Expenses: Rose to $16.62 million (from $9.28 million) due to increased clinical site activities, drug product costs, and higher personnel costs.
  • G&A Expenses: Rose to $7.71 million (from $5.51 million) primarily due to increased personnel and share-based compensation.
• Net Loss: Net loss widened to $21.49 million in Q2 2025 compared to $11.70 million in Q2 2024. This includes a $0.51 million gain from discontinued operations (royalties and asset adjustments from the Isoray sale).
• Liquidity: Cash and short-term investments decreased from $226.92 million at year-end 2024 to $191.58 million at June 30, 2025, reflecting operational burn and capital expenditures.

Guidance, Outlook, and Risks

Outlook and Funding: Management believes current cash resources of $191.6 million are sufficient to fund planned operations into late 2026. The company anticipates a significant increase in expenses, particularly in R&D, as it advances clinical trials for VMT-α-NET, VMT01, and PSV359.

Clinical Progress:

• VMT-α-NET (Neuroendocrine Tumors): Cohort 2 closed with 46 patients treated. Cohort 3 opened in June 2025 with a dose of 6 mCi. Interim data showed no dose-limiting toxicities and confirmed responses in some patients.
• VMT01 (Melanoma): Fast Track Designation granted by FDA. Cohort 3 (1.5 mCi) opened for monotherapy and combination with nivolumab.
• PSV359 (Solid Tumors): First patient treated in April 2025; two patients treated as of July 31, 2025.

Risks and Contingencies:

• Capital Requirements: The company expects to require additional capital to achieve profitability and may need to raise funds through equity or debt, which could be dilutive.
• Supply Chain: A "take-or-pay" purchase order with the U.S. Department of Energy commits the company to purchasing approximately $8.4 million of thorium-228 in 2025-2026.
• Legal: Settlement negotiations are ongoing regarding a stockholder lawsuit; the company has accrued $0.2 million for this liability.
• Regulatory: Risks include potential FDA workforce reductions or funding cuts impacting review timelines.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $191.6 million cash balance against the projected burn rate into late 2026, considering the $8.4 million DOE commitment.
• Capital Raising: Monitor the status of the $250 million ATM agreement and any potential dilutive equity offerings required to fund operations beyond 2026.
• Clinical Milestones: Track safety and efficacy data from the newly opened Cohort 3 of VMT-α-NET and the combination therapy trials for VMT01.
• Manufacturing Capacity: Assess the progress of facility modifications in Houston, Chicago, Los Angeles, and Somerset, NJ, to ensure they meet CGMP requirements for commercial scale-up.
• Discontinued Operations: Confirm the realization of royalty payments from GT Medical regarding the divested Isoray business.